findmyKOL
Clinical trialNCT05934331RecruitingPhase 2Interventional

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

SponsorLaNova Medicines Zhejiang Co., Ltd.Enrollment276Malignant Neoplasms of Digestive Organs
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Shanghai East Hospital

    Shanghai, China

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Jul 2023
Primary completion
1 Jul 2026
Completion
1 Jul 2028
Last update posted
12 Sept 2025
Registered enrollment
276
Registry id
NCT05934331

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.